Pfizer INC Form 4 insider transactions

Director James C. Smith reports acquisition of phantom stock units representing deferred compensation from Pfizer.

Director James Quincey reports acquisition of phantom stock units representing deferred director's compensation.

Director Shantanu Narayen reports acquisition of phantom stock units representing deferred director's compensation.

Director Joseph Echevarria reports acquisition of phantom stock units representing deferred compensation from Pfizer.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of phantom stock units under the company's deferred compensation plan.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 1,905 phantom stock units through the company's deferred compensation plan.

Executive Vice President Andrew Baum reports the acquisition of stock appreciation rights (SARs) convertible to Pfizer common stock.

Pfizer's Chief Financial Officer, David Denton, acquired stock appreciation rights (SARs) that will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Executive Vice President Aamir Malik acquired stock appreciation rights (SARs) convertible to 371,824 shares of Pfizer common stock, according to a Form 4 filing with the SEC.

Executive Vice President Alexandre de Germay acquired stock appreciation rights (SARs) for 371,824 shares of Pfizer common stock, exercisable in 2030.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the acquisition and disposal of company stock, including restricted stock units and stock appreciation rights, according to a Form 4 filing.

Executive Vice President of Pfizer, Sally Susman, reports acquisition of stock appreciation rights convertible to Pfizer common stock.

Executive Vice President Payal Sahni acquired stock appreciation rights convertible to 206,569 shares of Pfizer common stock.

Executive Vice President Michael McDermott acquired stock appreciation rights convertible to Pfizer common stock, according to a Form 4 filing.

Executive Vice President Douglas M. Lankler acquired stock appreciation rights convertible to 371,824 shares of Pfizer common stock.

Executive Vice President Lidia Fonseca reports acquisition of Pfizer stock appreciation rights.

Pfizer's CEO, Albert Bourla, was granted stock appreciation rights that will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Christoffel Boshoff, President of R&D at Pfizer, acquired 495,765 stock appreciation rights (SARs) on March 4, 2025, which will be settled in Pfizer common stock on March 4, 2030, subject to vesting requirements.

Jennifer B. Damico, SVP & Controller at Pfizer Inc., reports the earn-out and subsequent transactions related to stock appreciation rights.

Christoffel Boshoff, President of R&D at Pfizer, reports acquisition and disposal of common stock related to performance share awards.

Sally Susman, Executive Vice President of Pfizer, reports the earn-out and subsequent transactions related to stock appreciation rights.

Payal Sahni, Executive Vice President of Pfizer, reports the earn-out of stock appreciation rights and related transactions on February 27, 2025.

Executive Vice President Michael McDermott reports the earn-out of stock appreciation rights and related transactions involving Pfizer common stock.

Executive Vice President Douglas M. Lankler reports the earn-out of stock appreciation rights and related transactions involving Pfizer Inc. common stock.

Executive Vice President Lidia Fonseca reports the earn-out of stock appreciation rights and related transactions involving Pfizer common stock.

Pfizer's Chairman and CEO, Albert Bourla, executed stock appreciation rights and adjusted his holdings of Pfizer common stock on February 27, 2025.

Jennifer B. Damico, SVP & Controller at Pfizer Inc., reported the withholding of 377 common stock shares to cover tax obligations upon the vesting of restricted stock units on February 24, 2025.

Christoffel Boshoff, President of R&D at Pfizer, amends a previous SEC Form 4 filing to include a transaction involving the withholding of shares to cover tax obligations.

Executive Vice President Michael McDermott of Pfizer Inc. reported the withholding of 3,220 common stock shares to cover tax obligations upon the vesting of restricted stock units.

Christoffel Boshoff, President of R&D at Pfizer, reports acquisition and disposal of common stock related to performance share awards.